Year: 2019

Communiqué – Paris, le 6 décembre, 2019Forte détérioration du marché à Hong KongSMCP revoit son objectif de marge d’Ebitda ajusté pour 2019et confirme ses perspectives de croissance du chiffre d’affaires annuelSMCP annonce aujourd’hui la révision de son objectif 2019 de marge d’Ebitda ajusté principalement en raison de la forte détérioration du marché à Hong Kong, provoquée par une baisse importante du trafic et par des fermetures temporaires de points de vente au cours de ces dernières semaines. Cette détérioration aura un impact important sur la marge d’Ebitda du Groupe. Dans une moindre mesure, la performance plus faible que prévu de Claudie Pierlot, dont l’exposition aux marchés internationaux en forte croissance est beaucoup plus limitée, affectera également la marge du Groupe.Dans les autres régions et marques, le Groupe...

Basel, Switzerland, December 06, 2019 – Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that sales of the antifungal Cresemba® (isavuconazole) by Pfizer in Europe and Israel exceeded the threshold triggering a sales milestone payment to Basilea of USD 7 million.Basilea is entitled to receive sales milestone payments upon Pfizer’s cumulative Cresemba sales in Pfizer’s licensed territories exceeding certain thresholds. The first sales milestone was triggered early in 2019 and amounted to USD 5 million. Pfizer is currently commercializing Cresemba in many European countries, including France, Germany, Italy, Spain and the U.K, as well as in Israel and in Singapore, the first launched country in the Asia Pacific region.David Veitch, Chief Executive Officer of Basilea, said: “We are very pleased that the continued strong sales performance...

Basel, 06. Dezember 2019 – Basilea Pharmaceutica AG (SIX: BSLN) gab heute bekannt, dass die von Pfizer mit dem Antimykotikum Cresemba® (Isavuconazol) in Europa und Israel erzielten Umsätze die Schwelle überschritten haben, durch die eine Meilensteinzahlung an Basilea in Höhe von USD 7 Mio. ausgelöst wird.Basilea hat Anspruch auf kommerzielle Meilensteine, wenn die kumulierten Cresemba-Umsätze von Pfizer in deren Lizenzgebieten bestimmte Schwellenwerte überschreiten. Der erste Umsatzmeilenstein wurde Anfang 2019 ausgelöst und belief sich auf USD 5 Mio. Pfizer vermarktet Cresemba derzeit in vielen europäischen Ländern, darunter Frankreich, Deutschland, Italien, Spanien und Grossbritannien sowie in Israel und in Singapur, dem ersten Land im asiatisch-pazifischen Raum, in dem Cresemba lanciert wurde.David Veitch, Basileas Chief Executive...

Once-daily QMF149 met primary endpoint of lung function improvement and key secondary endpoint of asthma control improvement versus mometasone furoate1 QMF149 showed improvement in peak expiratory flow, exacerbation rates, rescue medication use versus mometasone furoate among other secondary endpoints1    Improvement in lung function was observed in high dose QMF149 versus a high dose LABA/ICS standard-of-care in certain additional secondary endpoints1   Basel, December 6, 2019 — Novartis today announced data from the 52-week pivotal Phase III PALLADIUM clinical trial which demonstrated that QMF149, a once-daily fixed-dose combination of indacaterol acetate and mometasone furoate (IND/MF) in development, was superior to mometasone furoate (MF) at medium and high doses in improving lung function, meeting the primary endpoint1. Statistically...

WISeKey launches its new WISeID digital identity ecosystemGeneva & Zug, Switzerland, December 6, 2019 – WISeKey International Holding Ltd (“WISeKey”, NASDAQ: WKEY, SIX: WIHN), a leading cybersecurity and IoT company today announced the launch of its new WISeID digital identity portfolio of services.WISeID is an innovative approach to people’s identity able to protect online interactions for individuals and companies. WISeID provides users with a Digital Identity that can be used to secure email communication, digitally sign documents with legal validity and it’s complemented with features such as dual factor authentication and single sign-on. WISeID is based on the WISeKey/OISTE Root of Trust and integrates innovative blockchain technologies to distribute the identity attributes and build federated ecosystems.WISeID is accessible...

MONT-SAINT-GUIBERT, Belgium, Dec. 06, 2019 (GLOBE NEWSWIRE) — Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today announced that the Company has received €2.5 million in non-dilutive funding. The amount is comprised of €2.1 million in non-dilutive funding from the SPW-Recherche of the Walloon Region, which will support the development of the company’s CAR-T candidates for the treatment of solid tumors, and €0.4 million of non-refundable tax incentive from Belgian Public Health Insurer.Filippo Petti, chief executive officer of Celyad, commented, “These latest additions of non-dilutive funding awarded by the Walloon Region and the Belgian government continues to support the ongoing development of our CAR-T cell therapy platform...

SHANGHAI, China, Dec. 05, 2019 (GLOBE NEWSWIRE) — GDS Holdings Limited (“GDS” or the “Company”) (Nasdaq: GDS) today announced the pricing of a public offering by it of 5,494,505 American Depositary Shares (“ADSs”), each representing eight of its Class A ordinary shares, at a public offering price of US$45.50 per ADS. The underwriters have been granted a 30-day option to purchase up to an additional 824,175 ADSs from GDS at the same price.The offering is expected to close on December 10, 2019, subject to customary closing conditions.GDS intends to use approximately US$190 million of the net proceeds from this offering to fund a portion of the cash consideration and assumed liabilities for the acquisition of three data centers at a campus located in Shunyi district, Beijing, which we refer to as Beijing 10, Beijing 11 and Beijing 12...

LONGVIEW, Texas, Dec. 05, 2019 (GLOBE NEWSWIRE) — Friedman Industries, Incorporated (NYSE—American; Trading Symbol: FRD) The Board of Directors (the “Board”) of Friedman Industries, Incorporated, a Texas-based company engaged in pipe manufacturing, steel processing and steel and pipe distribution, declared on December 5, 2019, a cash dividend of $0.02 per share on the Common Stock of the Company. The Company will pay the cash dividend on February 7, 2020 to shareholders of record at the close of business on January 10, 2020. This dividend marks the Company’s 192nd consecutive quarterly cash dividend with the Company having paid a cash dividend every quarter since becoming publicly traded in 1972.Dividends are declared at the discretion of the Board and reviewed on a quarterly basis. With the declaration of today’s dividend, the...

What you need to know:Verizon and Sony showed off how Verizon 5G Ultra Wideband, Sony’s transmitter box and 5G device can support live sports broadcastsTest showed how 5G connected cameras can stream high definition video content to remote production teams where wired cameras are not practicalNew 5G proof of concept conducted with NBC Sports at Houston Texans game at NRG Stadium on Dec. 1stNEW YORK, Dec. 05, 2019 (GLOBE NEWSWIRE) — Verizon, Sony Imaging Products & Solutions Inc. and Sony Mobile Communications Inc. joined forces with NBC Sports to test how 5G can change the way live sports broadcasts are captured and produced. During the Houston Texans vs New England Patriots football game at NRG Stadium on December 1st, 2019, a camera person from NBC Sports captured video of the game on the field using Sony’s PXW-Z450 shoulder...

DAVENPORT, Iowa, Dec. 05, 2019 (GLOBE NEWSWIRE) — Lee Enterprises, Incorporated (NYSE: LEE), a leading provider of high quality, trusted, local news and information, and a major platform for advertising in 50 markets, has scheduled an audio webcast and conference call for Thursday, December 12, 2019, at 9 a.m. Central Time. Lee plans to issue a news release before market open that day with preliminary results for its fourth fiscal quarter ended September 29, 2019.The live webcast will be accessible at lee.net and will be available for replay 24 hours later. Several analysts have been invited to ask questions on the call. Questions from other participants may be submitted by participating in the webcast. The call also may be monitored on a listen-only conference line by dialing (toll free) 800-309-1256 and entering a conference pass...